FOLLISTIM Drug Profile
✉ Email this page to a colleague
Summary for Tradename: FOLLISTIM
| High Confidence Patents: | 4 |
| Applicants: | 2 |
| BLAs: | 3 |
| Drug Prices: | Drug price information for FOLLISTIM |
| Recent Clinical Trials: | See clinical trials for FOLLISTIM |
Recent Clinical Trials for FOLLISTIM
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Ferring Pharmaceuticals | Phase 2 |
| Center for Human Reproduction | Phase 1/Phase 2 |
| Michigan Reproductive Medicine | Phase 4 |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for FOLLISTIM Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for FOLLISTIM Derived from Company Disclosures
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. | FOLLISTIM AQ | follitropin beta | Injection | 021273 | ⤷ Sign Up | 2017-01-15 | Company disclosures |
| Organon Usa Llc, A Subsidiary Of Organon & Co. | FOLLISTIM AQ CARTRIDGE | follitropin beta | Injection | 021211 | ⤷ Sign Up | 2015-06-16 | Company disclosures |
| Organon Usa Llc, A Subsidiary Of Organon & Co. | FOLLISTIM AQ CARTRIDGE | follitropin beta | Injection | 021211 | ⤷ Sign Up | 2017-01-15 | Company disclosures |
| Organon Usa Llc, A Subsidiary Of Organon & Co. | FOLLISTIM AQ CARTRIDGE | follitropin beta | Injection | 021211 | ⤷ Sign Up | 2018-07-23 | Company disclosures |
| Organon Usa Llc, A Subsidiary Of Organon & Co. | FOLLISTIM AQ CARTRIDGE | follitropin beta | Injection | 021211 | ⤷ Sign Up | 2018-07-23 | Company disclosures |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for FOLLISTIM Derived from Patent Text Search
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. | FOLLISTIM | follitropin beta | For Injection | 020582 | ⤷ Sign Up | 2033-03-11 | Patent claims search |
| Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. | FOLLISTIM | follitropin beta | For Injection | 020582 | ⤷ Sign Up | 2024-12-29 | Patent claims search |
| Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. | FOLLISTIM | follitropin beta | For Injection | 020582 | ⤷ Sign Up | 2029-05-13 | Patent claims search |
| Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. | FOLLISTIM | follitropin beta | For Injection | 020582 | ⤷ Sign Up | 2029-01-29 | Patent claims search |
| Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. | FOLLISTIM | follitropin beta | For Injection | 020582 | ⤷ Sign Up | 2037-01-05 | Patent claims search |
| Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. | FOLLISTIM | follitropin beta | For Injection | 020582 | ⤷ Sign Up | 2038-07-09 | Patent claims search |
| Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. | FOLLISTIM | follitropin beta | For Injection | 020582 | ⤷ Sign Up | Patent claims search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for FOLLISTIM
Supplementary Protection Certificates for FOLLISTIM
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 122010000011 | Germany | ⤷ Sign Up | PRODUCT NAME: CORIFOLLITROPIN ALFA; REGISTRATION NO/DATE: EU/1/09/609/001-002 20100125 |
| SZ 17/2001 | Austria | ⤷ Sign Up | PRODUCT NAME: CHORIOGONADOTROPHIN ALFA |
| SPC/GB01/030 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: RECOMBINANT CHORIOGONADOTROPIN ALFA; REGISTERED: UK EU/1/00/165/001-006 20010202 |
| SZ 6/2010 | Austria | ⤷ Sign Up | PRODUCT NAME: CORIFOLLITROPIN ALFA |
| C960004 | Netherlands | ⤷ Sign Up | PRODUCT NAME: RECOMBINANT HUMAAN FOLLIKELSTIMULEREND HORMOON; REGISTRATION NO/DATE: EU/1/95/001/001 - EU/1/95/001/016 19951020 |
| SZ 5/1996 | Austria | ⤷ Sign Up | PRODUCT NAME: REKOMBINANTES HUMANES FOLLIKELSTIMULIERENDES HORMON |
| 6/2010 | Austria | ⤷ Sign Up | PRODUCT NAME: CORIFOLLITROPIN ALFA; REGISTRATION NO/DATE: EU/1/09/609/001-002 20100125 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
